Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Felodipine + lisinopril is a combination of two antihypertensive agents used to treat high blood pressure. Felodipine is a long-acting dihydropyridine calcium channel blocker that works by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure[3][6][8]. Lisinopril is an angiotensin-converting enzyme (ACE) inhibitor that prevents the conversion of angiotensin I to angiotensin II, resulting in vasodilation and decreased aldosterone secretion, which also lowers blood pressure[5]. This combination targets different mechanisms within the cardiovascular system for additive antihypertensive effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on felodipine + lisinopril.